First Tracks Biotherapeutics TRAX Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, First Tracks Biotherapeutics insiders sold $66.76 million of stock on the open market (4.74Mn shares) and made no open-market purchases.

• By number of insiders, First Tracks Biotherapeutics saw 2 insiders sell on the open market over the past 12 months and none buy.
• Ecor1 Capital, LLC (10% owner) sold the most First Tracks Biotherapeutics stock on the open market over the past 12 months, $65 million (4.71Mn shares), most recently on April 20, 2026.
• The latest open-market trade in TRAX stock by an insider was a sale of 39.27K shares for $1.76 million by J. Anthony Ware (Director) on September 2, 2026.
• Outside the open market, First Tracks Biotherapeutics insiders acquired 53.92K shares through option exercises and conversions over the past 12 months.
• Per Business Quant data, First Tracks Biotherapeutics insiders hold 3.29Mn shares in total based on their latest Form 4 filings, or 9.30% of the 35.39Mn shares outstanding; that total is up 0.04% from 3.29Mn shares at the end of Q2 2026.
• Of the 3.29Mn shares held by First Tracks Biotherapeutics insiders, 117.46K shares (3.57%) are held directly and 3.17Mn shares (96.43%) indirectly, through trusts, partnerships, family members and other entities.
• Holdings in First Tracks Biotherapeutics stock are reported by 7 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• TRAX's largest insider holders by reported holdings are Ecor1 Capital, LLC (10% owner, 3.17Mn shares), John P. Schmid (Director, 37.65K shares) and Rita Jain (Director, 19.19K shares).
• The largest insider, Ecor1 Capital, LLC, holds 96.43% of TRAX's insider total.
• In the past year, 12 insiders of First Tracks Biotherapeutics submitted 41 Form 4 filings reporting trades, awards or other transactions.
• The insider data for TRAX reflects Form 4 filings through September 17, 2026.